Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
1.730
+0.030 (1.76%)
At close: Nov 13, 2026, 4:00 PM EST
1.760
+0.030 (1.73%)
After-hours: Nov 13, 2026, 7:30 PM EST

Voyager Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
25.1140.3780250.0140.9137.42
Revenue Growth
-19.82%-49.53%-68.00%511.16%9.33%-78.14%
Cost of Revenue
104.57132.27124.5992.1755.7673.79
Gross Profit
-79.46-91.9-44.59157.84-14.86-36.37
Selling, General & Admin
30.0636.4435.9235.8230.9837.25
Operating Expenses
30.0636.4435.9235.8230.9837.25
Operating Income
-109.52-128.34-80.51122.01-45.84-73.62
Interest Expense
------0.39
Interest & Investment Income
6.8910.6218.3311.721.79-
Other Non Operating Income (Expenses)
1.661.650.6202.65-
EBT Excluding Unusual Items
-100.97-116.08-61.56133.74-41.39-74.01
Merger & Restructuring Charges
-3.5-3.5----
Gain (Loss) on Sale of Investments
-----2.81
Asset Writedown
---2.78---
Other Unusual Items
-----5-
Pretax Income
-104.47-119.58-64.34133.74-46.39-71.2
Income Tax Expense
0.060.140.671.410.02-
Net Income
-104.53-119.72-65132.33-46.41-71.2
Net Income to Common
-104.53-119.72-65132.33-46.41-71.2
Net Income Growth
------
Shares Outstanding (Basic)
605958433838
Shares Outstanding (Diluted)
605958453838
Shares Change
3.01%1.77%29.39%16.20%1.83%0.86%
EPS (Basic)
-1.74-2.04-1.133.08-1.21-1.89
EPS (Diluted)
-1.74-2.04-1.132.97-1.21-1.89
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-109.83-135.06-18.8374.66-15-55.13
Free Cash Flow Per Share
-1.82-2.30-0.331.68-0.39-1.46
Gross Margin
--227.62%-55.74%63.13%-36.32%-97.21%
Operating Margin
-436.18%-317.89%-100.64%48.80%-112.05%-196.76%
Profit Margin
-416.32%-296.53%-81.25%52.93%-113.45%-190.29%
Free Cash Flow Margin
-437.43%-334.53%-23.54%29.86%-36.67%-147.36%
EBITDA
-105.79-124.28-75.78126.46-39.65-68.45
EBITDA Margin
---94.72%50.58%-96.92%-182.96%
D&A For EBITDA
3.734.064.734.446.195.17
EBIT
-109.52-128.34-80.51122.01-45.84-73.62
EBIT Margin
---100.64%48.80%-112.05%-196.76%
Effective Tax Rate
---1.05%--
SEC Filings: 10-K · 10-Q